U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

The lack of funding is expected to set back decades' worth of progress against HIV, according to public health experts.

Eunice wept bitterly almost every night after she was diagnosed with HIV in 2015. The 40-year-old single mother feared ...

The government is now targeting 15,000 Ugandans for new HIV/AIDS data study COVER STORY | RONALD MUSOKE | On May 29, the ...

The Trump administration's decision to halt a $258 million HIV vaccine research program has sparked widespread concern. This ...

The Trump administration’s decision to substantially restrict access to a vital HIV prevention tool – PEPFAR-funded preexposure prophylaxis, or PrEP – would cut off ongoing treatment for millions of ...

Set up in 2003 by George W Bush in response to a spiralling pandemic, Pepfar forms the backbone of the global response to HIV, funding drugs, prevention and research in more than 50 countries.

As government clinics take on HIV patients who were previously treated by Pepfar-funded projects, the treatment of conditions ...

With PEPFAR facing precarious uncertainty, shifting priorities and dwindling expertise raise alarms. Will the U.S. Congress intervene?

In his first hours as US president, Donald Trump signed an order freezing most foreign aid for 90 days — this included ...

Equatorial Guinea is facing a shortage of antiretroviral drugs, in a country where approximately 62,000 people live with HIV and AIDS, the health ministry said Friday.